Frequency- and state-dependent blockade of human ether-a-go-go-related gene K + channel by arecoline hydrobromide

Chinese Medical Journal

Volumn 125, Issue 6, 2012, Pages 1068-1075

  Zhao, Xu Yan ^a   Liu, Yu Qi ^a   Fu, Yi Cheng ^a   Xu, Bin ^a   Gao, Jin Liao ^a   Zheng, Xiao Qin ^a   Lin, Min ^a   Chen, Mei Yan ^a   Li, Yang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Anti arrhythmic agent; Arecoline hydrobromide; Frequency dependent manner; I hERG current; State dependent manner

Indexed keywords

ARECOLINE; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; FREQUENCY MODULATION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; PATCH CLAMP; POTASSIUM CURRENT;

ACTION POTENTIALS; ARECOLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS;

EID: 84862262521     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.06.020     Document Type: Article

References (31)

1. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269: 92-95.
2. + channels in the mouse heart exerts anti-arrhythmic activity. Cardiovasc Res 2005; 65: 128-137.
3. + channel. Open-channel block by methanesulfonanilides. Circ Res 1996; 78: 499-503.
4. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned hERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 212-219.
5. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96: 195-215.
6. + current by dofetilide. Circ Res 1993; 72: 75-83.
7. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiological effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissues. J Cardiovasc Pharmacol 1991; 18: 167-174.
8. Nattel S, Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984; 229: 283-291.
9. Carlsson L, Almgren O, Duker G QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit. Etiology and interventions. J Cardiovasc Pharmacol 1990; 16: 276-285.
10. Wang G, Hu B. Research progress of arecoline. Int J Pathol Clin Med (Chin) 2010; 30: 171-175.
11. Zhang CJ, Lü FJ, Tai JX, Wang ZN, Fu Q. Quantitative determination of alkaloids in areca nut and its products by RP-IP-HPLC. Food Sci (Chin) 2008; 29: 345-347.
12. Zhang CJ, Lü FJ, Tao HT Research progress of constituents and functions of betel nuts. Food Nutr China (Chin) 2008; 6: 50-53.
13. Zhang HY, Li Y. Effect of arecoline on transient outward potassium current in rat ventricular myocytes. Chin J New Drugs Clin Remedies (Chin) 2006; 25: 349-352.
14. Lin XM, Li Z, Hu BR, Xia GJ, Yao WX, Xiang JZ. Effects of arecoline on calcium channel currents and caffeine-induced calcium release in isolated single ventricular myocyte of guinea pig. J Huazhong Univ Sci Technol (Chin) 2002; 4: 279-280.
15. Busch AE, Eigenberger B, Jurkiewicz NK, Salata JJ, Pica A, Suessbrich H, et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. Br J Pharmacol 1998; 123: 23-30.
16. + current, IKr. Circulation 1996; 94: 2938-2946.
17. Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of hERG Single-channel currents and block by dofetilide. Circulation 1996; 94: 2572-2579.
18. Wang J, Hua W, Zhu J, Yang YM, Wang FZ, Pu JL, et al. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation. Chin Med J 2010; 123: 2028-2033.
19. Sanguinetti MC, Keating MT. Role of delayed rectifier potassium channels in cardiac repolarization and arrhythmias. News Physiol Sci 1997; 12: 152-157.
20. Tseng GN IKr: the hERG channel. J Mol Cell Cardiol 2001; 33: 835-849.
21. Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, et al. Drug binding interactions in the inner cavity of hERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 2006; 69: 509-519.
22. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (hERG) potassium channels. J Pharmacol Exp Ther 2002; 300: 543-548.
23. + channel. J Mol Cell Cardiol 2004; 36: 151-160.
24. + channels by vesnarinone. Mol Pharmacol 2001; 60: 244-253.
25. + current by antifungal drug miconazole. Br J Pharmacol 2005; 144: 840-848.
26. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (hERG) potassium channels. J Pharmacol Exp Ther 2002; 300: 543-548.
27. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
28. Akar FG Use-dependent modulation of myocardial conduction by a new class of hERG agonists: deal breaker or cherry on top? J Cardiovasc Electrophysiol 2010; 21: 930-932.
29. Tsujimae K, Suzuki S, Murakami S, Kurachi Y. Frequency-dependent effects of various IKr blockers on cardiac action potential duration in a human atrial model. Am J Physiol Heart Circ Physiol 2007; 293: H660-H669.
30. Gussak I, Litwin J, Morganroth J. Proarrhythmic potential of reverse use-dependent drugs. J Electrocardiol 2007; 40: 432-433.
31. Khavandi A, Walker PR. Flecainide cardiotoxicity precipitated by electrolyte imbalance: caution with thiazide diuretics. Emerg Med J 2007; 24: e26.